Newsroom

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry (KOAR), a landmark multicenter study, in the journal Transplantation. The third manuscript from KOAR investigated the correlation between early post-transplant AlloSure Kidney donor-derived cell-free DNA (dd-cfDNA) levels and thr...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended September 30, 2026. To view the detailed third quarter 2026 earnings press release and presentation, please visit the company’s investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) today, to discuss these financial results and provide an update on the company. The webcast may be accessed...

FAIRFAX, Va.--(BUSINESS WIRE)--Everforth ECS Secures NGA Contract Extension With Potential Value Exceeding $200M, Advancing Operational GEOINT Capabilities...

BOSTON & SAN DIEGO--(BUSINESS WIRE)--Elucid, an innovator of AI-powered cardiovascular imaging software, today announced results from ELUCIDATE, presented at the annual Transcatheter Cardiovascular Therapeutics Conference (TCT 2026). The ELUCIDATE study, which supported Elucid’s recent U.S. Food and Drug Administration (FDA) 510(k) clearance of the FFR-IQTM software, demonstrated 92.9 percent vessel-level diagnostic accuracy for Elucid’s FFR-IQ technology versus invasive fractional flow reserve...

HERNDON, Va.--(BUSINESS WIRE)--Sophia Learning announces a new partnership with Rocky Mountain College of Art + Design....

BURLINGAME, Calif.--(BUSINESS WIRE)--Upstart Publishes October 2026 Originations and Latest UMI...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update. “We entered 2026 with a clear plan to deliver multiple important clinical and operational milestones this year and we have made significant progress exec...

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences: Stifel 2026 Healthcare Conference Fireside Chat Date and Time: Tuesday, November 10, 2026 at 9:20 AM ET Loc...

NEW YORK--(BUSINESS WIRE)--Bowhead Specialty Holdings Inc. (“Bowhead”, the “Company” or “us”) (NYSE: BOW), a specialty lines insurance group focused on providing casualty, professional liability and healthcare liability insurance products, delivered through complementary “craft” and “digital” underwriting models, today announced financial results for the third quarter ended September 30, 2026(1). Third Quarter 2026 Highlights Gross written premiums increased 10.8% to $256.4 million. Net income...

AUSTIN, Texas--(BUSINESS WIRE)--Vital Farms (Nasdaq: VITL), a Certified B Corporation that offers a range of ethically produced foods nationwide, today reported financial results for its third quarter ended September 27, 2026. Financial highlights for the third quarter ended September 27, 2026, compared to the third quarter ended September 28, 2025, where applicable, include: Net Revenue of $182.2 million, a decrease of 8.4% year over year and an increase of 9.7% sequentially from the second qu...